| Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting | 06/02 01:13 | prnewswire.com |
| Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting | 06/01 20:00 | prnewswire.com |
| Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting | 06/01 08:10 | businesswire.com |
| Nuvation Bio to Present at the Jefferies Global Healthcare Conference | 05/29 16:05 | businesswire.com |
| Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update | 05/14 16:05 | businesswire.com |
| Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 04/24 10:01 | businesswire.com |
| Nuvation Bio Completes Acquisition of AnHeart Therapeutics | 04/10 16:01 | businesswire.com |
| Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate | 03/31 10:00 | seekingalpha.com |
| Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer | 03/28 08:00 | businesswire.com |
| Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction | 03/25 07:00 | businesswire.com |